ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,235
-0,18%
Bitcoin
61 372,68
-0,12%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aeglea BioTherapeutics Inc (AGLE)

  7. Aeglea BioTherapeutics Inc (AGLE) Actualités

AGLE

Aeglea BioTherapeutics (AGLE)

Aeglea BioTherapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AGLE
DateHeureSourceTitreSymboleSociété
30/04/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AGLEAeglea BioTherapeutics Inc
25/04/202422h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
25/04/202422h40Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AGLEAeglea BioTherapeutics Inc
25/04/202422h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGLEAeglea BioTherapeutics Inc
02/04/202422h36Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AGLEAeglea BioTherapeutics Inc
01/04/202422h06Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AGLEAeglea BioTherapeutics Inc
20/03/202412h14Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AGLEAeglea BioTherapeutics Inc
18/03/202421h06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AGLEAeglea BioTherapeutics Inc
14/03/202421h12Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AGLEAeglea BioTherapeutics Inc
27/11/202322h32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
27/11/202314h30PR Newswire (US)Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBDNASDAQ:AGLEAeglea BioTherapeutics Inc
22/11/202323h00PR Newswire (US)Aeglea BioTherapeutics Announces Grants of Inducement AwardsNASDAQ:AGLEAeglea BioTherapeutics Inc
15/11/202323h18Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:AGLEAeglea BioTherapeutics Inc
14/11/202321h13Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AGLEAeglea BioTherapeutics Inc
09/11/202322h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGLEAeglea BioTherapeutics Inc
09/11/202322h05PR Newswire (US)Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:AGLEAeglea BioTherapeutics Inc
31/10/202301h00PR Newswire (US)Aeglea BioTherapeutics to Participate in Upcoming November Investor ConferencesNASDAQ:AGLEAeglea BioTherapeutics Inc
07/10/202303h40Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:AGLEAeglea BioTherapeutics Inc
14/09/202323h03PR Newswire (US)Aeglea BioTherapeutics to Participate in Upcoming September ConferenceNASDAQ:AGLEAeglea BioTherapeutics Inc
07/09/202314h40PR Newswire (US)Aeglea BioTherapeutics Announces Reverse Stock SplitNASDAQ:AGLEAeglea BioTherapeutics Inc
05/09/202313h00PR Newswire (US)Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-JonesNASDAQ:AGLEAeglea BioTherapeutics Inc
11/08/202313h00PR Newswire (US)Aeglea BioTherapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:AGLEAeglea BioTherapeutics Inc
07/08/202322h25Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AGLEAeglea BioTherapeutics Inc
27/07/202313h00PR Newswire (US)Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica PharmaNASDAQ:AGLEAeglea BioTherapeutics Inc
06/07/202322h04Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AGLEAeglea BioTherapeutics Inc
30/06/202323h24Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:AGLEAeglea BioTherapeutics Inc
23/06/202322h30PR Newswire (US)Aeglea BioTherapeutics Announces Grant of Inducement AwardsNASDAQ:AGLEAeglea BioTherapeutics Inc
23/06/202315h18Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AGLEAeglea BioTherapeutics Inc
22/06/202314h17PR Newswire (US)Aeglea BioTherapeutics Announces Acquisition of Spyre TherapeuticsNASDAQ:AGLEAeglea BioTherapeutics Inc
11/05/202313h06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AGLEAeglea BioTherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AGLE

Dernières Valeurs Consultées

NYSE
JPM
JP Morgan Chase
NYSE
MRK
Merck
NYSE
NKE
Nike
EU
DG
Vinci
NASDAQ
AMZN
Amazon.com
EU
PX4
SBF 120
EU
AI
Air Liquide
EU
MC
Lvmh Moet Hennessy Louis...
EU
AF
Air FranceKLM
NYSE
KO
Coca Cola
EU
VK
Vallourec
EU
PX1
CAC 40
SPI
SP500
S&P 500
FTSE
UKX
FTSE 100
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés